Financial Data and Key Metrics Changes - Total revenue for Q1 2025 decreased by 5.8% to $4.2 million compared to $4.5 million in the same period last year [11] - SaaS revenue grew by 9.8% to $1.5 million, driven by early successes in payables automation [11] - Professional services revenue decreased by 13.2% to $2.2 million, accounting for 51% of total revenue compared to 55% last year [12] - Net loss for Q1 was $728,000, compared to a net loss of $175,000 for the same period last year [13] - Adjusted EBITDA for the quarter was $77,000, down from $673,000 in Q1 2024 [14] Business Line Data and Key Metrics Changes - SaaS revenue increased due to payables automation, while professional services revenue declined due to timing issues [11][12] - The gross margin percentage increased to 67.6%, driven by a better revenue mix and improved SaaS margins [12][13] Market Data and Key Metrics Changes - The company experienced a record-breaking week with over $2.4 million in new project contracts, indicating strong demand from state agencies and commercial clients [9] - Recent political events have created uncertainty, but management is optimistic about future demand for their products and services [10] Company Strategy and Development Direction - The company is focusing on transforming into a predominantly SaaS-driven business with a diverse suite of solutions [5] - Investments are being made in sales and marketing, as well as IT infrastructure, to enhance customer trust and cybersecurity [7] - The company plans to continue scaling its business and expects to see returns on these investments in late 2025 and beyond [7][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledges headwinds in the building industry due to high interest rates and tariffs but remains optimistic about future growth [23] - The company expects to grow revenues year-over-year for fiscal 2025, particularly in SaaS revenues, while maintaining positive adjusted EBITDA [16] Other Important Information - The company has temporarily paused aggressive debt prepayments to focus on sales and marketing initiatives [15] - A shelf registration has been filed to strengthen the balance sheet and act quickly on market opportunities [15] Q&A Session Summary Question: How many implementations will you have and what would those mean in terms of annual recurring revenue? - The company will have about 22 to 23 customers using the SaaS product for payables automation [19] Question: How is the implementation of purchase orders progressing? - The first release of payables order was launched in April, with positive initial feedback [20][21] Question: Are there any customer hesitations regarding implementation timing? - Hesitation is more related to market conditions rather than the company's product [23] Question: Are the new orders in professional services stable in terms of margin opportunities? - Yes, the company has a strong backlog with over $3 million of work queued [27] Question: Does the company still serve over 600 K-12 customers? - Yes, the company has launched new products in the K-12 market and is seeing good growth [28][29]

Biodesix (BDSX) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Please be advised that today's conference is being recorded. I would now like to hand the conference over to Chris Brenzi. You may begin. Speaker1 Thank you, operator, and good afternoon, everyone. Today, Biodesix released results from the first quarter of twenty twenty five. Leading the call today will be Scott Hutton, Chief Executive Officer. He is joined by Robin Harpurkawi, Chief Financial Officer. An audio recording of today's call ...

GRAIL (GRAL) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good day, ladies and gentlemen, and welcome to the GRAIL First Quarter twenty twenty five Earnings Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that this conference call is being recorded. Grail Investor Relations, please begin. Speaker1 Thanks, operator, and thanks, everyone, for joining us today. On today's call are Bob Bergu ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $8.5 million, an 11% increase from $7.6 million in Q1 2024 [7] - Gross margin improved to 60%, up from 59% in Q1 2024 [10] - Cash and cash equivalents decreased to $12.4 million from $20.1 million at the end of 2024 [11] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 9% to $4.7 million, driven by a $1.2 million increase in product revenue [8] - Neurosurgery Navigation revenue surged 70% to $3.3 million, attributed to higher sales of new product offerings [9] - Capital Equipment and Software revenue fell 63% to $500,000 due to fewer new placements of navigation and laser units [10] Market Data and Key Metrics Changes - The company activated two new sites in Q1 2025, which were both capital placements [51] - The introduction of the three point zero navigation software has allowed expansion into operating rooms, enhancing market reach [14] Company Strategy and Development Direction - The company aims to extend its lead in cell and gene therapy through a comprehensive drug delivery ecosystem [4] - Plans to evolve the product portfolio to focus on fast, simple, and predictable workflows to increase hospital efficiency [5] - The company is pursuing global scale by expanding its installed base and generating more access to its ecosystem [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for additional cell and gene therapy platforms to gain approvals in the next two years [16] - The recent partnership with Overland Capital provides the company with the necessary funding to execute its strategy [6] - Management anticipates that operational cash burn will continue to increase but expects to generate meaningful cash flow as new drugs come online [31] Other Important Information - The company has implemented a Pathfinder subscription program to smooth capital revenue recognition over time [22] - The three point zero navigation software has been well received, with positive feedback from surgeons regarding efficiency and accuracy [18] Q&A Session Questions and Answers Question: Are there initiatives that can be prioritized now with access to incremental capital? - Management confirmed that there are opportunities to accelerate hiring and expand preclinical resources in response to partner requests [29] Question: How does the new capital runway relate to achieving sustained breakeven? - Management believes the new debt facility can support the company towards cash breakeven, especially with the flexibility of an interest-only period [31] Question: How is the neuro franchise tracking relative to expectations? - Management stated that the neuro franchise is on plan and expects significant growth throughout the year, with potential upside from new product launches [34] Question: What is the expected mix of MRI versus OR procedures in the future? - Management indicated that while MRI procedures currently dominate, there is potential for OR procedures to grow faster as new therapies are introduced [40] Question: What is the status of GLP certification and customer interest? - Management confirmed that they are on track for GLP certification by the end of the year and noted strong interest from pharma partners for studies once certified [42][46]

Genasys (GNSS) Q2 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 At this time, it is my pleasure to turn the floor over to your host, Brian Alger, SVP, Investor Relations and Corporate Development. Welcome, Brian. The floor is yours. Speaker1 Good afternoon. Welcome to Genesis' fiscal twenty twenty five second quarter results conference call. I'm Brian Alger, SVP, Investor Relations and Corporate Development for Genesis. With me on the call today are Richard Danforth, our CEO and Dennis Kwan, the comp ...

Financial Data and Key Metrics Changes - The company's Q1 2025 GAAP net investment income and core NII was $6,800,000 or $0.02 per share, down from $8,000,000 or $0.03 per share in Q4 2024, and below the quarterly distribution of $0.03 per share [6][18] - NAV per share at the end of Q1 was $12.11, representing a 1.6% decrease from the prior quarter, impacted by net realized losses and markdowns totaling $2,600,000 [6][18] - The weighted average effective yield on income-producing debt investments decreased to 12.1% at the end of Q1 from 12.5% in Q4 2024 [9][18] Business Line Data and Key Metrics Changes - Gross capital deployments in Q1 totaled $45,500,000, with net deployments of $26,100,000 after repayments and sales of $19,400,000 [6][9] - The portfolio mix at the end of Q1 consisted of approximately 90.3% first lien, senior secured debt, with a mix of two-thirds sponsor and one-third non-sponsor deals [7][9] - Nonaccrual investments totaled 8.8% of the debt portfolio, up from 7.2% in the prior quarter [13][18] Market Data and Key Metrics Changes - The STRS JV portfolio had an aggregate fair value of $310,200,000 with an average effective yield of 10.8%, down from 11.1% in Q4 [8][20] - The lending market has seen a 25 to 50 basis point increase in pricing due to increased volatility, but most of that premium has dissipated recently [15][18] - The M&A market has slowed significantly, with many deals being put on hold due to uncertainty in the economic environment [41][42] Company Strategy and Development Direction - The company continues to focus on the non-sponsor market, where there are better risk-return profiles and less competition [16][18] - The company added a new coverage region in Nashville, Tennessee, to enhance non-sponsor and off-the-run sponsor origination capabilities [16][18] - The company is actively monitoring the debt capital markets for opportunities to optimize or refinance its capital structure [21][18] Management's Comments on Operating Environment and Future Outlook - Management noted that challenges in the portfolio are more company-specific rather than related to the overall economy, with no signs of a recession yet [10][18] - The company expects a decent amount of refinancing activity in the second half of the year as prepayment penalties on higher-rate deals expire [46][18] - Management is cautious about the environment for deal closures in Q3, anticipating a quiet period due to the current market conditions [42][18] Other Important Information - The company declared a first-quarter distribution of $0.03 per share, consistent with the prior quarter, and will continue to evaluate its quarterly distribution based on core earnings power [22][18] - Cash resources at the end of Q1 were approximately $19,600,000, including $8,200,000 in restricted cash [21][18] Q&A Session Summary Question: Update on Telestream and its return to accrual status - Management indicated progress on restructuring Telestream, hoping to complete it by May, which would allow a portion of the existing debt to return to cash-paying status [26][27] Question: Dividend update and spillover income - Spillover income was approximately $28,400,000, with a current dividend run rate equating to about $8,950,000 in distributions, indicating a shortfall for Q1 [33][35] Question: Market conditions and bid-ask spreads - Management noted that good companies without significant tariff or recession risk are trading at high multiples, while those with risks are seeing buyers being conservative [40][41]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 12% year over year, reaching $28.3 million in Q1 2025, driven by solid new sales and renewal activity [4][14] - Adjusted EBITDA grew 50% year over year to $4.5 million, highlighting operational leverage and a profitable growth strategy [4][15] - GAAP net loss was approximately $1.5 million, or a loss of $0.12 per share, compared to a net loss of $2.9 million in the prior year [18] Business Line Data and Key Metrics Changes - The renewal of two contracts with the New York City Police Department contributed approximately $3.5 million in catch-up revenue [4][15] - The company went live with four new cities and one expansion in Q1, with a robust international ShotSpotter pipeline [5] - Resource Router is currently deployed in over 20 agencies, more than double its installed base in less than 18 months [10] Market Data and Key Metrics Changes - The company expects accelerated traction with ShotSpotter internationally in the second half of 2025 and early 2026 [6] - The California Assembly Bill 2975 mandates hospitals to deploy weapon protection systems by 2027, creating a significant market opportunity [11][12] - The company anticipates annual recurring revenue (ARR) to increase from $95.6 million at the beginning of 2025 to approximately $110 million at the beginning of 2026 [20] Company Strategy and Development Direction - The company is focused on expanding its platform and data aggregation capabilities to position itself as a leader in public safety technology [3] - Investments are being made in AI capabilities, particularly for the Crime Tracer and SafePoint solutions [17][12] - The company is taking risk mitigation efforts to address potential headwinds related to municipal funding and budgets [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of their offerings and the differentiated value they bring to cities like Chicago [6] - The company remains vigilant about headwinds but believes it is well-positioned to drive revenue and ARR growth for 2025 [13] - Management reaffirmed full-year revenue guidance of $111 million to $113 million, while slightly reducing adjusted EBITDA guidance to 20% to 22% [19][20] Other Important Information - The company ended Q1 with $11.7 million in cash and cash equivalents, compared to $13.2 million at the end of Q4 2024 [19] - The company repurchased 33,493 shares at an average price of $15.04 for approximately $504,000 in Q1 2025 [19] Q&A Session Summary Question: How does the company manage the pipeline across its broader suite of tools? - Management indicated that each product solution has its own pipeline metrics, with a solid pipeline across the platform, particularly in Resource Router and Crime Tracer [22][23] Question: What early feedback has been received on the revamped SafePoint product? - Management noted success in the healthcare vertical, with proof of concept deployments underway in major healthcare chains [24][25] Question: Will there be meaningful bookings from Plate Ranger this year? - Management expects bookings to be in the $1 million range, with significant revenue increases anticipated next year [28][29] Question: What is the expected sales cycle for SafePoint given the 2027 requirement? - Management indicated that the opportunity for SafePoint is more of a 2026 opportunity, with traction being made in other markets [37][38] Question: How should revenue progression be viewed for Q2? - Management suggested a reduction in Q2 revenue, with expectations for growth in Q3 and Q4 as investments begin to pay off [48] Question: What is the annualized cost of SafePoint compared to traditional solutions? - Management stated that SafePoint charges about $20,000 per year per lane, offering a compelling solution compared to traditional methods [59][60] Question: What are the international opportunities and timing for expansion? - Management highlighted excitement about returning to Brazil and ongoing discussions for expansion in other Latin American countries [66][68]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported net revenue of $20.4 million, with $17.1 million from MyPlifa, $0.1 million from Olpruva, and $2.3 million in net reimbursements from the French EAP for Aramcholamol [29][30] - Operating expenses for Q1 were $22.8 million, a decrease of $0.6 million compared to the same quarter last year [30] - The net loss for Q1 2025 was $3.1 million, compared to a net loss of $16.6 million in the same quarter a year ago [30][31] - Total cash, cash equivalents, and investments as of March 31, 2025, were $68.7 million, a decrease of $6.8 million from December 31, 2024 [30][31] Business Line Data and Key Metrics Changes - MyPlifa's launch has exceeded expectations, with 122 prescription enrollment forms received since launch, indicating that approximately one-third of diagnosed NPC patients in the U.S. have been enrolled [20][21] - Olpruva received a total of 28 prescription enrollment forms since its initial availability, with five forms received in Q1 2025 [12][27] - The company has achieved 38% of covered lives for MyPlifa, which is in line with expectations at this stage of the launch [21][22] Market Data and Key Metrics Changes - The company is focusing on expanding MyPlifa's availability outside the U.S., with plans for a marketing authorization application in Europe in the second half of the year [11] - The European market for NPC is well established, with approximately 1,100 people estimated to be living with the disease [11] Company Strategy and Development Direction - The company is executing on four strategic pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation [5][8] - The focus is on bringing innovative therapies to patients with rare diseases, with a strong emphasis on MyPlifa as a cornerstone treatment for NPC [17][33] - The company is also assessing strategic alternatives for its Phase III ready asset KP1077 for rare sleep disorders [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early success of MyPlifa and the refined marketing strategy for Olpruva, indicating a strong position for future growth [33] - The company believes it is well positioned to support its strategic priorities and execute on its long-term vision, independent from capital markets [31][32] Other Important Information - The company has successfully monetized its Pediatric Rare Disease Priority Review Voucher, adding $148.3 million of non-dilutive capital to its balance sheet [8][31] - The company is committed to patient access and comprehensive patient services through its in-house program, Amplify Assist [27] Q&A Session Summary Question: Details on the number of patients on MyPlifa and reimbursement status - The company received 122 enrollments since launch, with the majority of patients actively on the drug, while some are in the benefits investigation process [36] Question: Reasons for reimbursement denials for MyPlifa - Initial denials are common for rare disease products, primarily due to prior authorization requirements, but the company has been successful in securing coverage through medical exception processes [39][40] Question: Visibility on patient cohorts and enrollment cadence - The company estimates around 600 undiagnosed patients and 300 diagnosed patients, with ongoing efforts to raise awareness and facilitate treatment [47][59] Question: Inventory levels at the end of the quarter - The company is managing inventory closely and maintaining target levels as it supports patient needs during the early launch phase [50] Question: Qualitative metrics on refill rates and patient retention - The majority of patients receiving active drug have continued to refill, reflecting the clinical benefit and durability of MyPlifa [54] Question: Coverage details and impact on patient access - 38% of covered lives have access to MyPlifa, with ongoing efforts to increase this percentage as more plans evaluate the product [63][64]

a.k.a. Brands Holding (AKA) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Please note that this call is being recorded. I will now turn the conference over to our host, Emily Schwartz, Investor Relations. Thank you. You may begin. Speaker1 Good afternoon. Thank you for joining AK Brands to discuss our first twenty twenty five results released this afternoon, which can be found on our website at ir.akabrands.com. With me on the call today is Keiran Long, Chief Executive Officer and Kevin Grant, Chi ...

Fractyl Health (GUTS) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Fractal Health's First Quarter twenty twenty five Financial Results and Business Updates Call. As a reminder, this conference call is being recorded. At this time, all participants are in listen only mode. There will be a question and answer session following management's prepared remarks. I'll now turn the call over to Brian Lucay, Head of Investor Relations and Corporate Development at Fractal. Bri ...